Home › FDA Approves Expanded Use of Agilent Assay as Keytruda CDx for Cervical Cancer

FDA Approves Expanded Use of Agilent Assay as Keytruda CDx for Cervical Cancer

Jun 12, 2018

NEW YORK (GenomeWeb) – Agilent Technologies said after the close of the market on Tuesday that the US Food and Drug Administration has approved the Dako PD-L1 IHC 22C3 pharmDx assay for expanded use as a companion diagnostic test for Keytruda (pembrolizumab) for cervical cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02
Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Molecular Diagnostics

  1. Premaitha Licenses NIPT Tech From Illumina Under Settlement

  2. Cepheid Fingerstick HCV Test Receives CE-IVD Clearance

  3. Noridian Issues Draft LCD for GenomeDx Prostate Biopsy Genomic Classifier

  4. Qiagen, NeuMoDx Ink Partnership, Merger Agreement

  5. India's MolBio Brings Tuberculosis MDx to Point of Care With Help From FIND

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.